Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
196 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2016', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects - The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Attention Deficit Hyperactivity Disorder (ADHD) Overview 9 Therapeutics Development 10 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 10 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 11 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 12 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 16 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 21 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 25 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 26 Alcobra Ltd 26 Amarantus Bioscience Holdings, Inc. 27 APeT Holding BV 28 Arbor Pharmaceuticals, LLC. 29 BCWorld Pharm Co. Ltd. 30 Collegium Pharmaceutical, Inc. 31 Curemark, LLC 32 Domain Therapeutics SA 33 DURECT Corporation 34 Ensysce Biosciences Inc. 35 H. Lundbeck A/S 36 Heptares Therapeutics Limited 37 Highland Therapeutics, Inc. 38 Hisamitsu Pharmaceutical Co., Inc. 39 Integrative Research Laboratories Sweden AB 40 Intra-Cellular Therapies, Inc. 41 INVENT Pharmaceuticals, Inc. 42 KemPharm, Inc. 43 Luc Therapeutics, Inc. 44 Medgenics Inc. 45 Merck & Co., Inc. 46 Neos Therapeutics, Inc. 47 NeuroDerm Ltd. 48 Neurovance, Inc. 49 NLS Pharma Group 50 P2D Bioscience 51 Polleo Pharma Limited 52 Reviva Pharmaceuticals Inc. 53 Shire Plc 54 Sunovion Pharmaceuticals Inc. 55 Supernus Pharmaceuticals, Inc. 56 Taisho Pharmaceutical Holdings Co., Ltd. 57 TRImaran Pharma, Inc. 58 Vernalis Plc 59 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 65 Assessment by Route of Administration 67 Assessment by Molecule Type 69 Drug Profiles 71 (nicotine + opipramol hydrochloride) - Drug Profile 71 AR-08 - Drug Profile 72 BCWPE-003 - Drug Profile 73 BLI-1008 - Drug Profile 74 BNC-375 - Drug Profile 75 CB-8411 - Drug Profile 76 centanafadine IR - Drug Profile 77 centanafadine SR - Drug Profile 78 CM-4612 - Drug Profile 79 CTX-1301 - Drug Profile 80 CTX-1302 - Drug Profile 81 dasotraline hydrochloride - Drug Profile 82 dextroamphetamine - Drug Profile 83 dextroamphetamine MR - Drug Profile 84 eltoprazine - Drug Profile 85 etiguanfacine - Drug Profile 88 guanfacine hydrochloride ER - Drug Profile 89 histamine dihydrochloride - Drug Profile 91 HTL-1071 - Drug Profile 92 INV-170 - Drug Profile 93 IRL-752 - Drug Profile 94 ITI-214 - Drug Profile 95 KP-415 CR - Drug Profile 96 lisdexamfetamine dimesylate - Drug Profile 98 mazindol - Drug Profile 102 Metadoxine ER - Drug Profile 103 methylphenidate hydrochloride ER - Drug Profile 105 methylphenidate hydrochloride MR - Drug Profile 106 methylphenidate hydrochloride SR - Drug Profile 107 methylphenidate hydrochloride XR - Drug Profile 108 MGS-0028 - Drug Profile 109 molindone hydrochloride ER - Drug Profile 110 NFC-1 - Drug Profile 111 niacinamide CR - Drug Profile 112 NLS-3 - Drug Profile 113 NLS-4 - Drug Profile 114 NT-0201 - Drug Profile 115 P-001 - Drug Profile 116 PBF-509 - Drug Profile 117 PD-2005 - Drug Profile 118 PD-3044 - Drug Profile 120 PFR-08001 - Drug Profile 121 PFR-8026 - Drug Profile 122 RP-5063 - Drug Profile 123 SHP-465 - Drug Profile 124 Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 125 Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 126 Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia - Drug Profile 127 Small Molecules to Agonize NMDA2D for ADHD - Drug Profile 128 Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 129 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 130 Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 131 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 132 Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 133 V-81444 - Drug Profile 134 Vaccine for CNS Disorders - Drug Profile 135 viloxazine hydrochloride ER - Drug Profile 136 vortioxetine hydrobromide - Drug Profile 137 VU-0238429 - Drug Profile 140 Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 141 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 178 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 183 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 184 Featured News & Press Releases 184 Appendix 191 Methodology 191 Coverage 191 Secondary Research 191 Primary Research 191 Expert Panel Validation 191 Contact Us 191 Disclaimer 192
List of Tables Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2016 14 Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Comparative Analysis by Unknown Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Development by Companies, H1 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2016 29 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2016 30 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 31 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H1 2016 32 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H1 2016 33 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 34 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H1 2016 35 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H1 2016 36 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Domain Therapeutics SA, H1 2016 37 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H1 2016 38 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc., H1 2016 39 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H1 2016 40 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Limited, H1 2016 41 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics, Inc., H1 2016 42 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 43 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 44 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 45 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 46 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H1 2016 47 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics, Inc., H1 2016 48 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Medgenics Inc., H1 2016 49 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H1 2016 50 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H1 2016 51 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H1 2016 52 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance, Inc., H1 2016 53 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H1 2016 54 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2016 55 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H1 2016 56 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 57 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2016 58 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 59 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H1 2016 60 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 61 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma, Inc., H1 2016 62 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis Plc, H1 2016 63 Assessment by Monotherapy Products, H1 2016 64 Assessment by Combination Products, H1 2016 65 Number of Products by Stage and Target, H1 2016 67 Number of Products by Stage and Mechanism of Action, H1 2016 70 Number of Products by Stage and Route of Administration, H1 2016 72 Number of Products by Stage and Molecule Type, H1 2016 74 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H1 2016 145 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2016 182 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H1 2016 183 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H1 2016 184 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H1 2016 185 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H1 2016 186 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2016 187
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
